Monday, 28 February 2011

ACASTI One Small Step From Going Public

Neptune Technologies & Bioressources
Basic Shares: 42.0 million
Fully diluted: 45.48 million

The news investors have been waiting for is nearly here after Neptune announced Monday it won conditional approval from the Toronto Stock Exchange to list its subsidiary, Acasti Pharma, on the Venture Index.

And it could all happen on or before March 21st, the final date Acasti's management expects to meet all the conditions the exchange set for a listing.

To read all the details, please click here.

In another announcement, Neptune reported it will be one of 400 companies presenting to a large California investors conference - the 23rd annual show called the Roth OC Growth Stock Conference on March 15th.

The same day and hour its presentation is given to an expected audience of 1,000 buy side investors, it will also be posted on Neptune's website.

Neptune also disclosed it has granted nearly 1.2 million incentive stock options to employees, officers and directors. The options carry an exercise prices of $2.50 and a three-year maturity.

To read the full news release, please click here.